Company
Sk Life
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
0
Originals and new uses
Phase 3 trials
14
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Xcopri approved NovelNov 21, 2019
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and AdultsPivotal-lookingRecruiting
SK Life Science, Inc.Industry
NCT05219617 · 252 participants (planned) · Start Apr 28, 2022 · Primary completion Feb 2027
Drug: Carisbamate · For: Seizures; Lennox Gastaut Syndrome
Sites: Palo Alto, California; Jacksonville, Florida; Orlando, Florida · 71 sites in all
Marketed drugs (1)
Newest FDA action first.
- Xcopri Cenobamate · 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.